Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.
Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust early revenue growth. Learn ...
The AI rally has left many other deserving stocks out in the cold. The case for Expedia Group, Total, Brink’s, and more.